✉ Email this page to a colleague
« Back to Dashboard
Huperzine-A is an investigational drug.
There have been 13 clinical trials for Huperzine-A. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Cognitive Dysfunction, Alzheimer Disease, and Hemorrhage. The leading clinical trial sponsors are U.S. Army Medical Research and Materiel Command, Yale University, and Shandong Luye Pharmaceutical Co., Ltd.
Recent Clinical Trials for Huperzine-A
|The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study||Second Affiliated Hospital, School of Medicine, Zhejiang University||Phase 4|
|The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study||Wanbangde Pharmaceutical Group Co., LTD||Phase 4|
|A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery||Second Affiliated Hospital of Wenzhou Medical University||N/A|